Uric acid and hypertension: a review of evidence and future perspectives for the management of cardiovascular risk

C Borghi, D Agnoletti, AFG Cicero, E Lurbe… - Hypertension, 2022 - Am Heart Assoc
Uric acid is the final product of purine metabolism, and its increased serum levels have been
directly involved in the pathogenesis and natural history of hypertension. The relationship …

[HTML][HTML] Elevated serum uric acid and cardiovascular disease: a review and potential therapeutic interventions

M Freilich, A Arredondo, SL Zonnoor, IM McFarlane - Cureus, 2022 - ncbi.nlm.nih.gov
Several landmark studies found a relationship between elevated serum uric acid (SUA)
levels and cardiovascular disease (CVD). In fact, the association between hyperuricemia …

Pathophysiological mechanisms of hypertension development induced by fructose consumption

C Xu, J Yu - Food & Function, 2022 - pubs.rsc.org
During the past several decades, there has been a dramatic increase in fructose
consumption worldwide in parallel with epidemics of metabolic diseases. Accumulating …

Effects of intensive urate lowering therapy with febuxostat in comparison with allopurinol on pulse wave velocity in patients with gout and increased cardiovascular risk …

G Desideri, M Rajzer, M Gerritsen… - European Heart …, 2022 - academic.oup.com
Aims Hyperuricaemia and gout are strongly related with traditional cardiovascular risk
factors and vascular damage. This study aimed to assess whether febuxostat and allopurinol …

Febuxostat ameliorates high salt intake-induced hypertension and renal damage in Dahl salt-sensitive rats

T Miura, A Sakuyama, L Xu, J Qiu… - Journal of …, 2022 - journals.lww.com
Objective: Several clinical studies have reported that xanthine oxidoreductase inhibitors
have antihypertensive and renal protective effects but their mechanisms have not been fully …

[HTML][HTML] Consensus on patients with hyperuricemia and high cardiovascular risk treatment: 2022

IE Chazova, YV Zhernakova, OA Kislyak… - Systemic …, 2022 - syst-hypertension.ru
After 3 years since the release of the first consensus on the management of patients with
hyperuricemia and high cardiovascular risk. During this time, new data appeared that …

[HTML][HTML] Консенсус по ведению пациентов с гиперурикемией и высоким сердечно-сосудистым риском: 2022

ИЕ Чазова, ЮВ Жернакова, ОА Кисляк… - Системные …, 2022 - cyberleninka.ru
Со времени выхода первого консенсуса по ведению пациентов с гиперурикемией и
высоким сердечно-сосудистым риском прошло 3 года. За это время появились новые …

Cardiological and rheumatological expert statement on the management of asymptomatic hyperuricemia in patients at high cardiovascular risk

M Barylski, B Batko, KJ Filipiak… - Rheumatology …, 2022 - journals.viamedica.pl
Cardiological and rheumatological expert statement on the management of asymptomatic
hyperuricemia in patients at high cardiov Page 1 43 www.journals.viamedica.pl Marcin Barylski1 …

[PDF][PDF] Kardiologiczno-reumatologiczne stanowisko ekspertów dotyczące leczenia bezobjawowej hiperurykemii u pacjentów obciążonych wysokim ryzykiem sercowo …

M Barylski, B Batko, KJ Filipiak, A Mamcarz… - Varia …, 2022 - journals.viamedica.pl
Kwas moczowy (UA, uric acid) to końcowy produkt metabolizmu puryn (endogennych i
egzogennych). W przypadku większości zwierząt UA jest dalej rozkładany do alantoiny …